Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
5.78
+0.14 (2.48%)
Jul 17, 2026, 3:46 PM EDT - Market open
Nuvation Bio Revenue
Nuvation Bio had revenue of $83.23M in the quarter ending March 31, 2026, with 2,598.70% growth. This brings the company's revenue in the last twelve months to $143.05M, up 1,205.52% year-over-year. In the year 2025, Nuvation Bio had annual revenue of $62.90M with 698.96% growth.
Revenue (ttm)
$143.05M
Revenue Growth
+1,205.52%
P/S Ratio
13.83
Revenue / Employee
$465,948
Employees
307
Market Cap
2.01B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.90M | 55.03M | 698.96% |
| Dec 31, 2024 | 7.87M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| Harmony Biosciences Holdings | 899.11M |
| UroGen Pharma | 140.49M |
| Viridian Therapeutics | 70.92M |
| Ocular Therapeutix | 52.04M |
| Monte Rosa Therapeutics | 42.95M |
| Nanobiotix | 38.27M |
| Taysha Gene Therapies | 7.47M |
NUVB News
- 7 days ago - 3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts - TipRanks
- 10 days ago - Nuvation Bio price target lowered to $19 from $20 at RBC Capital - TheFly
- 10 days ago - Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering - PRNewsWire
- 18 days ago - Nuvation Bio announces MHRA in UK approves MAA for taletrectinib - TheFly
- 18 days ago - Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom - PRNewsWire
- 21 days ago - Nuvation Bio prices upsized offering of $250M of convertible senior notes - TheFly
- 21 days ago - Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes - PRNewsWire
- 22 days ago - Nuvation Bio falls -10.1% - TheFly